Wednesday, May 17, 2023 11:24:41 AM
However, I do respect and understand your right to disagree with me. But, I will have to go where the evidence takes me.
I am looking at the preponderance of the evidence, not just 1 speech in 2022. I believe that the advantages of using poly-ICLC as an in vivo maturation and activation agent, have been known by Dr. Liau, Dr. Prins, and the other members of the team at UCLA, since 2014, or even before. They will take this knowledge and move forward, not backwards.
Dr. Prins even showed us in 2016, in this graphical depiction below, that poly-ICLC is now automatically included as an in vivo maturation and activation agent when treating patients with DCVax-L:
Recent NWBO News
Last Shot Hydration Drink Announced as Official Sponsor of Red River Athletic Conference • EQLB • Jun 20, 2024 2:38 PM
ATWEC Announces Major Acquisition and Lays Out Strategic Growth Plans • ATWT • Jun 20, 2024 7:09 AM
North Bay Resources Announces Composite Assays of 0.53 and 0.44 Troy Ounces per Ton Gold in Trenches B + C at Fran Gold, British Columbia • NBRI • Jun 18, 2024 9:18 AM
VAYK Assembling New Management Team for $64 Billion Domestic Market • VAYK • Jun 18, 2024 9:00 AM
Fifty 1 Labs, Inc Announces Acquisition of Drago Knives, LLC • CAFI • Jun 18, 2024 8:45 AM
Hydromer Announces Attainment of ISO 13485 Certification • HYDI • Jun 17, 2024 9:22 AM
